5 takeaways from BIO 2026 in San Diego — for everyone who couldn't be in the room 👇
The world's largest biotech gathering just wrapped, and 2026 was a milestone year. 20,000 leaders, four days of partnering, and the industry's 50th anniversary — biotech was born in California, and it came home to celebrate. An estimated 70,000 partnering meetings were scheduled through the BIO Partnering™ platform, with attendees from over 70 countries and 130+ sessions across 18 focus areas.
I wasn't on the floor this year, but I tracked the signal so you don't have to:
1. Dealmaking went into overdrive.
The "dual track" playbook is obsolete. Triple and even quadruple tracks are now the norm, with biotechs running an "all of the above" strategy across IPO, M&A, licensing, and funding at once. The fuel? A $65 billion year-to-date M&A swamp left investors with capital eager to be redeployed — to the point that companies file for an IPO on Friday and announce an acquisition by Monday.
A few names that captured the moment:
• AbbVie scooped up Apogee Therapeutics for roughly $10.9B, deepening its next-gen immunology pipeline beyond Skyrizi and Rinvoq.
• GSK acquired Nuvalent for about $10.6B, and Merck KGaA took out Bio-Techne at $11.3B to strengthen the tools side of biotech.
• Eli Lilly continued its buying spree, having committed over $25 billion in business development this year alone, including closing the $6.3B Centessa buyout.
2. A startup launched live with $230M and a triple-threat structure.
The boldest debut of the week: Serapha Bio launched to develop a one-and-done gene-editing treatment for the liver and lung disease AATD — threading a Chinese licensing deal, $230 million in funding, and a reverse merger with Boundless Bio all at once. A masterclass in modern deal architecture.
3. China became the conversation — not a side panel.
China's growing power in developing new drugs was central to much of the convention. The tone was more optimistic than in past years — speed, operational efficiency, and molecule generation came up repeatedly. Context worth knowing: China now contributes roughly 30% of the global biotech pipeline. The counterweight on stage: speed matters, but global regulatory acceptance remains the benchmark for worldwide impact.
4. AI grew up — and the bill is coming due.
The conversation shifted from hype to economics. Executives talked about moving fast on AI as early strategies reveal where it creates a competitive edge — while wrestling with its rising cost and whether it actually pays off.
5. The "why" stayed front and center.
Beyond deals and data, the Patient Advocacy Pavilion and Storytelling Stage were reminders that innovation extends beyond science alone. Fifty years in, the mission hasn't changed: better outcomes for patients.
The throughline? Capital is hunting, deals are getting creative, and the patient still has to win.
Next stop: BIO 2027 in Philadelphia, June 7–10.
Which of these shifts will define the next 12 months? I'd love your read 👇
One Story Changes Lives.
#bio2026 #biotech #healthtech #drugdevelopment #aiinhealthcare #lifesciences
